Table 2 Comparisons of demographic and clinical features between patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia with favorable and unfavorable final clinical responses
Outcome at the end of the initial treatment | Favorable outcome n = 67 | Unfavorable outcome n = 17 | P |
|---|---|---|---|
Demographics | |||
Male gender, n (%) | 43 (64.2) | 11 (64.7) | > 0.99 |
Age, mean (IQR), years | 68 (59–77) | 72 (48–85) | 0.82 |
MIC of teicoplanin ≥ 1.5 mg/L, n (%) | 22 (32.8) | 7 (41.2) | 0.57 |
Co-morbidities, n (%) | |||
Coronary artery disease | 14 (20.9) | 3 (17.6) | > 0.99 |
Diabetes mellitus | 30 (44.8) | 4 (23.5) | 0.17 |
Hypertension | 38 (56.7) | 5 (29.4) | 0.06 |
Solid tumor | 14 (20.9) | 5 (29.4) | 0.52 |
Hematology malignancy | 1 (1.5) | 0 | > 0.99 |
Liver cirrhosis | 4 (6.0) | 3 (17.6) | 0.14 |
Chronic obstructive pulmonary disease | 5 (7.5) | 2 (11.8) | 0.63 |
IV drug abuser | 2 (3.0) | 2 (11.8) | 0.18 |
Congestive heart failure | 13 (19.4) | 2 (11.8) | 0.73 |
End-stage renal disease | 17 (25.4) | 3 (17.6) | 0.75 |
Cerebral vascular accident | 21 (31.3) | 2 (11.8) | 0.14 |
Prosthetic device implantation | 27 (40.3) | 5 (29.4) | 0.58 |
Pittsburgh bacteremia score ≥ 4a | 14 (20.9) | 16 (94.1) | < 0.01* |
Source of bacteremiab, n (%) | |||
Catheter-related bacteremia | 15 (22.4) | 2 (11.8) | 0.50 |
Bone and joint infection | 20 (29.9) | 1 (5.9) | 0.06 |
Infective endocarditis | 2 (3.0) | 4 (23.5) | 0.01 |
Skin and soft infection | 16 (23.9) | 1 (5.9) | 0.17 |
Intra-abdominal infection | 0 | 1 (5.9) | 0.20 |
Urinary tract infection | 1 (1.5) | 0 | > 0.99 |
Pneumonia | 5 (7.5) | 3 (17.6) | 0.35 |
Primary bacteremia | 6 (9.0) | 3 (17.6) | 0.38 |
Adequate infection source control ratec n/N | 28/51 (54.9) | 2/4 (50.0) | > 0.99 |
Initial treatment group, n (%) | |||
Initial teicoplanin treatment group | 24 (35.8) | 4 (23.5) | 0.40 |
Initial ß-lactam treatment group | 43 (64.2) | 13 (76.5) | 0.40 |